Donald Hooker
Stock Analyst at Keybanc
(2.55)
# 2,118
Out of 5,182 analysts
81
Total ratings
55.95%
Success rate
9.22%
Average return
Main Sectors:
Stocks Rated by Donald Hooker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Overweight | $180 → $100 | $5.27 | +1,797.53% | 18 | Feb 23, 2022 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $450 → $390 | $173.89 | +124.28% | 5 | Feb 17, 2022 | |
| DGX Quest Diagnostics | Maintains: Overweight | $168 → $170 | $198.02 | -14.15% | 4 | Dec 13, 2021 | |
| IQV IQVIA Holdings | Maintains: Overweight | $270 → $290 | $173.26 | +67.38% | 4 | Nov 17, 2021 | |
| PHR Phreesia | Maintains: Overweight | $70 → $73 | $8.37 | +772.16% | 8 | Jul 12, 2021 | |
| RXRX Recursion Pharmaceuticals | Initiates: Overweight | $36 | $3.11 | +1,057.56% | 1 | May 11, 2021 | |
| AMWL American Well | Initiates: Sector Weight | n/a | $5.50 | - | 1 | Apr 16, 2021 | |
| VEEV Veeva Systems | Maintains: Overweight | $332 → $353 | $173.98 | +102.90% | 2 | Feb 17, 2021 | |
| HQY HealthEquity | Downgrades: Sector Weight | n/a | $84.63 | - | 11 | Dec 2, 2020 | |
| MMS Maximus | Maintains: Overweight | $80 → $84 | $62.38 | +34.66% | 2 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $2.25 | - | 8 | Jul 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $170 | $273.72 | -37.89% | 7 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $114.19 | - | 6 | Sep 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $68 → $46 | $0.76 | +5,952.63% | 2 | Nov 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $498.34 | - | 2 | Jul 10, 2017 |
Teladoc Health
Feb 23, 2022
Maintains: Overweight
Price Target: $180 → $100
Current: $5.27
Upside: +1,797.53%
Charles River Laboratories International
Feb 17, 2022
Maintains: Overweight
Price Target: $450 → $390
Current: $173.89
Upside: +124.28%
Quest Diagnostics
Dec 13, 2021
Maintains: Overweight
Price Target: $168 → $170
Current: $198.02
Upside: -14.15%
IQVIA Holdings
Nov 17, 2021
Maintains: Overweight
Price Target: $270 → $290
Current: $173.26
Upside: +67.38%
Phreesia
Jul 12, 2021
Maintains: Overweight
Price Target: $70 → $73
Current: $8.37
Upside: +772.16%
Recursion Pharmaceuticals
May 11, 2021
Initiates: Overweight
Price Target: $36
Current: $3.11
Upside: +1,057.56%
American Well
Apr 16, 2021
Initiates: Sector Weight
Price Target: n/a
Current: $5.50
Upside: -
Veeva Systems
Feb 17, 2021
Maintains: Overweight
Price Target: $332 → $353
Current: $173.98
Upside: +102.90%
HealthEquity
Dec 2, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $84.63
Upside: -
Maximus
Aug 7, 2020
Maintains: Overweight
Price Target: $80 → $84
Current: $62.38
Upside: +34.66%
Jul 6, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $2.25
Upside: -
Mar 30, 2020
Maintains: Overweight
Price Target: $212 → $170
Current: $273.72
Upside: -37.89%
Sep 23, 2019
Downgrades: Sector Weight
Price Target: n/a
Current: $114.19
Upside: -
Nov 13, 2017
Maintains: Overweight
Price Target: $68 → $46
Current: $0.76
Upside: +5,952.63%
Jul 10, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $498.34
Upside: -